Spruce Biosciences is progressing its TA-ERT treatment, potentially the first disease-modifying therapy for MPS IIIB, toward FDA approval. The treatment has shown durable normalization of key biomarkers and stabilization of cognitive and motor functions over six years, supporting an accelerated approval pathway. The company plans to submit a Biologics License Application (BLA) in Q4, with FDA feedback indicating acceptance of a surrogate endpoint, meaning no further clinical studies are expected before submission. Despite dilution, Spruce's financial position is strengthened, and its valuation appears undervalued compared to potential peak sales if TA-ERT is approved.
Crédit Agricole Brie Picardie conducted share buybacks totaling 15,648 shares between June 29 and July 3, 2026, with prices ranging from approximately €36.35 to €37.96 per share. These repurchases were made under the conditions of Article 5 of the MA...
Sanoma Corporation will publish its Half-Year Report for the period January to June 2026 on July 29, 2026. The report and related materials will be available on their website, followed by an analyst and investor conference held in Helsinki and access...
Sanoma Oyj will publish its half-year financial report for January to June 2026 on July 29, 2026, at around 8:30 AM. The report and related materials will be available immediately on Sanoma's investor website. An English-language briefing for analyst...
AMSilk and Ajinomoto Foods Europe (AFE) have expanded their partnership with a long-term manufacturing and supply agreement to scale industrial production of silk proteins. AFE will establish a dedicated production line at its Nesle, France site usin...
The global ambient light sensor market, valued at $3.81 billion in 2025, is projected to reach $9.54 billion by 2035 with a CAGR of 9.63%. Growth is fueled by rising demand for smart devices like smartphones and wearables, energy-efficient displays, ...
